All In Biotech

Drug Trial Radar · NCT07941388

A Phase I Study of INT-1868 Tablets in Healthy Adult Participants (INT-1868-I101)

A Phase I, Randomized, Double-blind, Placebo-controlled, Single and Multiple Ascending Dose Escalation, and Food-effect Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INT-1868 in Healthy Adult Participants

Last checked: Nov 20, 2026Latest source record: Nov 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

92

Planned (sponsor's estimate)

Start

Nov 9, 2026

Primary completion

Jun 17, 2027

Study completion Jul 17, 2027

Sponsor

Sponsor type
Industry
First posted
Nov 17, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 45 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

A Phase I, Randomized, Double-blind, Placebo-controlled, Single and Multiple Ascending Dose escalation, and Food-Effect Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of INT-1868 Tablets in Healthy Adult Participants. * Primary Objectives: 1\. To evaluate the safety and tolerability of INT-1868 tablets after single and multiple doses in healthy adult participants; * Secondary Objectives: 1\. To evaluate the PK characteristics of INT-1868 tablets after single and multiple doses in healthy adult participants; 2. To evaluate the effect of food on the PK characteristics of INT-1868 tablets; * Other Objectives: 1. To evaluate the PD characteristics of INT-1868 tablets after single and multiple doses in healthy adult participants; 2. To evaluate the PK characteristics of INT-1868 tablet metabolites (if applicable) after single and multiple doses in healthy adult participants; 3. To assess the effect of INT-1868 tablets on C-QTc; 4. To preliminarily evaluate the metabolic characteristics of INT-1868 tablets in humans.

Conditions

  • Atopic Dermatitis (AD)

Interventions

  • INT-1868 TabletsDrug

    Escalating doses of 2.5, 10, 30, 100, 200, 300 mg of INT-1868; Single dose administration; Oral administration

  • INT-1868 TabletsDrug

    Escalating doses of 10, 30, 100 mg, 200 mg of INT-1868; QD for 14 days; Oral administration

  • INT-1868 TabletsDrug

    100 mg INT-1868; Dosing on Day 1 (first dose) and Day 11 (second dose);Oral administration

  • INT-1868 PlaceboDrug

    INT-1868 Placebo;PO

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Adverse events(AEs)Time frame: SAD:From enrollment through the safety follow-up visit on Day 14 (SAD),Day 38 (MAD) or Day 21 (FE)
  2. Laboratory tests: Complete Blood CountTime frame: SAD:From enrollment through the safety follow-up visit on Day 14 (SAD),Day 38 (MAD) or Day 21 (FE)
  3. Physical examinationTime frame: SAD:From enrollment through the safety follow-up visit on Day 14 (SAD),Day 38 (MAD) or Day 21 (FE)
  4. Treatment-emergent potentially clinically significant abnormalities in vital signs:blood pressure (mmHg)Time frame: SAD:From enrollment through the safety follow-up visit on Day 14 (SAD),Day 38 (MAD) or Day 21 (FE)
  5. Treatment-emergent potentially clinically significant abnormalities in vital signs:pulse rate (bpm)Time frame: SAD:From enrollment through the safety follow-up visit on Day 14 (SAD),Day 38 (MAD) or Day 21 (FE)
  6. Treatment-emergent potentially clinically significant abnormalities in vital signs: respiratory rate (brpm)Time frame: SAD:From enrollment through the safety follow-up visit on Day 14 (SAD),Day 38 (MAD) or Day 21 (FE)
  7. Treatment-emergent potentially clinically significant abnormalities in vital signs: body temperature (℃)Time frame: SAD:From enrollment through the safety follow-up visit on Day 14 (SAD),Day 38 (MAD) or Day 21 (FE)
  8. The main parameters of the 12-lead electrocardiogram (ECG) examination: heart rate (bpm)Time frame: SAD:From enrollment through the safety follow-up visit on Day 14 (SAD),Day 38 (MAD) or Day 21 (FE)
  9. The main parameters of the 12-lead electrocardiogram (ECG) examination: PR Interval (milliseconds)Time frame: SAD:From enrollment through the safety follow-up visit on Day 14 (SAD),Day 38 (MAD) or Day 21 (FE)
  10. The main parameters of the 12-lead electrocardiogram (ECG) examination: QRS duration (milliseconds)Time frame: SAD:From enrollment through the safety follow-up visit on Day 14 (SAD),Day 38 (MAD) or Day 21 (FE)
  11. The main parameters of the 12-lead electrocardiogram (ECG) examination: QT interval (milliseconds)Time frame: SAD:From enrollment through the safety follow-up visit on Day 14 (SAD),Day 38 (MAD) or Day 21 (FE)
  12. The main parameters of the 12-lead electrocardiogram (ECG) examination: QTc (milliseconds)Time frame: SAD:From enrollment through the safety follow-up visit on Day 14 (SAD),Day 38 (MAD) or Day 21 (FE)

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Beijing Municipality -No. 101, Luyuan East Road, Tongzhou District, Beijing, China

    Beijing, Beijing Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.